Pharma Equity Group A/S

PEG A

DK0061155009

Investment Holding Companies

Delayed Nasdaq Copenhagen Other stock markets 03:08:39 2024-07-18 EDT			5-day change	1st Jan Change
0.309 ^DKK	-0.32%		+3.69%	-28.14%

05-17	Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-16	Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	CI

Blue Vision A/S: Direktørskifte

January 04, 2021 at 04:27 am

Dato: 04. januar 2021
Årets meddelelse nr.: 1

Blue Vision A/S: Direktørskifte

Bestyrelsen har modtaget Peter Hauge Jensen’s meddelelse om dennes endelige fratrædelse af stillingen som administrerende direktør for Blue Vision A/S.

Bestyrelsen har ansat Jeanette G. Borg som selskabets nye direktør.

Med venlig hilsen
Blue Vision A/S

På bestyrelsens vegne
Bestyrelsesformand
Peter Ole Jensen

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	05-16	CI
Pharma Equity Group A/S announced that it expects to receive DKK 1 million in funding	05-15	CI
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	04-09	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	04-05	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	03-20	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	02-06	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	01-24	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	01-22	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	01-21	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01-17	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	11-16	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	11-16	CI
Pharma Equity Group A/S Approves Board Appointments	11-02	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	23-10-31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	23-08-15	MT
Pharma Equity Group A/S Announces Board Changes	23-06-15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	23-06-14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	23-06-14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	23-03-23	CI

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

2024-08-15 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-28.14%	46.48M
INVESTOR AB	+27.21%	85.49B
INVESTMENT AB LATOUR	+14.41%	18.3B
KOÇ HOLDING	+62.91%	17.45B
AB INDUSTRIVÄRDEN	+8.00%	14.45B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+24.26%	13.04B
L E LUNDBERGFÖRETAGEN AB	-1.86%	12.69B
HAL TRUST	+0.53%	11.28B
MERITZ FINANCIAL GROUP INC.	+39.26%	10.98B
SK SQUARE CO., LTD.	+84.60%	9.38B